ScreenerHero

ANIXAnixa Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · anixa.com
3.710USD0.00%Mkt Cap: 126.23M $P/E: —

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a ch…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap126.23M $
Enterprise Value107.39M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.93M $
Revenue/Share—
Last Price3.710 USD
Fiscal Year EndOct 2025
MR QuarterApr 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS03528H1095
Valuation
P/E (Trailing)—
P/E (Forward)-11.58
PEG-0.11
EV/EBITDA—
EV/Revenue—
P/S—
P/B8.41
EPS (TTM)-0.29
EPS (Forward)-0.31
52W Range
2.32044% of range5.460
52W High5.460 USD
52W Low2.320 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-72.07%
ROA-67.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.17M $
CapEx (TTM)—
FCF Margin—
FCF Yield-2.88%
Net Debt-13.50M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio9.79
Quick Ratio9.15
Book Value/Sh0.4270 USD
Cash/Share0.4020 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJun 26, 2015
Analyst Consensus
Rating—
Target (Mean)10.00 USD
Upside (mean)+169.5%
Target Range7.000 USD – 14.00 USD
$7.000+169.5% to mean$14.00
# Analysts4
Ownership
Shares Out.34.02M
Float32.15M
Insiders5.50%
Institutions14.16%
Short Interest
Short Ratio3.8d
Short % Float3.39%
Short % Out.3.21%
Shares Short1.09M
Short (prev mo.)885.94K
Technical
SMA 503.168 (+17.1%)
SMA 2003.208 (+15.6%)
Beta0.52
S&P 52W Chg18.16%
Avg Vol (30d)244.25K
Avg Vol (10d)209.59K
Technical Indicators
RSI (14)64.8
MACD0.0834
MACD Signal0.0728
MACD Hist.+0.0106
BB Upper3.801 USD
BB Middle3.448 USD
BB Lower3.095 USD
BB Width20.46%
ATR (14)0.2173 USD
Vol Ratio (20d)0.76x